Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 44 | 2023 | 396 | 16.530 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 599 | 2.960 |
Why?
|
| Stroke Volume | 19 | 2023 | 100 | 2.840 |
Why?
|
| Pandemics | 9 | 2022 | 287 | 2.760 |
Why?
|
| Humans | 62 | 2023 | 17762 | 2.410 |
Why?
|
| Influenza Vaccines | 5 | 2023 | 273 | 2.210 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2022 | 53 | 2.040 |
Why?
|
| Hospitalization | 14 | 2023 | 808 | 2.010 |
Why?
|
| Influenza, Human | 5 | 2023 | 265 | 1.830 |
Why?
|
| Cardiology | 3 | 2022 | 30 | 1.680 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 49 | 1.660 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 56 | 1.650 |
Why?
|
| Biphenyl Compounds | 7 | 2022 | 10 | 1.340 |
Why?
|
| Aminobutyrates | 7 | 2022 | 18 | 1.330 |
Why?
|
| Treatment Outcome | 12 | 2022 | 1260 | 1.190 |
Why?
|
| Drug Combinations | 7 | 2022 | 41 | 1.190 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 238 | 1.180 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2022 | 20 | 1.160 |
Why?
|
| Valsartan | 6 | 2022 | 11 | 1.140 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 66 | 1.120 |
Why?
|
| Neprilysin | 4 | 2022 | 10 | 0.970 |
Why?
|
| Aged | 16 | 2023 | 6150 | 0.920 |
Why?
|
| Betacoronavirus | 3 | 2020 | 35 | 0.910 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 18 | 0.900 |
Why?
|
| Hospital Mortality | 7 | 2022 | 145 | 0.830 |
Why?
|
| Registries | 6 | 2023 | 472 | 0.820 |
Why?
|
| Cardiovascular System | 1 | 2022 | 4 | 0.820 |
Why?
|
| Vaccination | 5 | 2023 | 655 | 0.820 |
Why?
|
| Curriculum | 1 | 2022 | 35 | 0.810 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 6 | 0.800 |
Why?
|
| Heart Diseases | 2 | 2021 | 77 | 0.790 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 44 | 0.790 |
Why?
|
| Tetrazoles | 4 | 2022 | 15 | 0.760 |
Why?
|
| Eye Diseases | 1 | 2021 | 6 | 0.760 |
Why?
|
| Medicine | 1 | 2021 | 22 | 0.760 |
Why?
|
| Enalapril | 1 | 2021 | 8 | 0.760 |
Why?
|
| Polypharmacy | 1 | 2021 | 13 | 0.760 |
Why?
|
| Patient Discharge | 2 | 2021 | 154 | 0.750 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 85 | 0.720 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 43 | 0.710 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2018 | 13 | 0.710 |
Why?
|
| Male | 17 | 2023 | 10106 | 0.670 |
Why?
|
| United States | 10 | 2022 | 4003 | 0.630 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 186 | 0.610 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 6 | 0.580 |
Why?
|
| Heart Rate | 1 | 2017 | 41 | 0.560 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 51 | 0.560 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2022 | 86 | 0.550 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 1 | 0.550 |
Why?
|
| Middle Aged | 11 | 2023 | 7988 | 0.540 |
Why?
|
| Female | 15 | 2023 | 12740 | 0.540 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 50 | 0.540 |
Why?
|
| Buprenorphine | 1 | 2016 | 48 | 0.520 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 132 | 0.500 |
Why?
|
| Time Management | 1 | 2014 | 1 | 0.480 |
Why?
|
| Operating Rooms | 1 | 2014 | 3 | 0.480 |
Why?
|
| Clinical Medicine | 1 | 2014 | 3 | 0.470 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 30 | 0.460 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 1923 | 0.460 |
Why?
|
| Shock, Cardiogenic | 3 | 2022 | 6 | 0.440 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 172 | 0.440 |
Why?
|
| Renin-Angiotensin System | 3 | 2022 | 17 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 755 | 0.390 |
Why?
|
| Angiotensins | 2 | 2022 | 3 | 0.380 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 27 | 0.370 |
Why?
|
| Medicare | 2 | 2022 | 205 | 0.370 |
Why?
|
| Aftercare | 2 | 2021 | 49 | 0.350 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 1213 | 0.340 |
Why?
|
| Peptide Fragments | 2 | 2021 | 27 | 0.330 |
Why?
|
| Outpatients | 2 | 2020 | 110 | 0.310 |
Why?
|
| Comorbidity | 2 | 2021 | 597 | 0.300 |
Why?
|
| Chronic Disease | 2 | 2022 | 428 | 0.290 |
Why?
|
| Cohort Studies | 2 | 2022 | 2586 | 0.260 |
Why?
|
| Double-Blind Method | 3 | 2021 | 155 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2021 | 1279 | 0.240 |
Why?
|
| American Heart Association | 2 | 2022 | 49 | 0.240 |
Why?
|
| Troponin T | 2 | 2021 | 10 | 0.240 |
Why?
|
| Troponin | 2 | 2022 | 9 | 0.230 |
Why?
|
| Critical Care | 2 | 2022 | 71 | 0.230 |
Why?
|
| Cause of Death | 3 | 2019 | 181 | 0.220 |
Why?
|
| Risk Factors | 3 | 2021 | 3356 | 0.220 |
Why?
|
| Time Factors | 4 | 2021 | 1093 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2461 | 0.210 |
Why?
|
| Cardiotonic Agents | 2 | 2020 | 12 | 0.210 |
Why?
|
| Myeloproliferative Disorders | 1 | 2022 | 1 | 0.210 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 8 | 0.210 |
Why?
|
| Leukemia | 1 | 2022 | 9 | 0.210 |
Why?
|
| Acute Disease | 2 | 2020 | 142 | 0.200 |
Why?
|
| Patient Care Team | 1 | 2023 | 113 | 0.200 |
Why?
|
| Heart Injuries | 1 | 2021 | 1 | 0.200 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 3 | 0.200 |
Why?
|
| Drug Labeling | 1 | 2021 | 14 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 34 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 328 | 0.190 |
Why?
|
| Myocardium | 1 | 2021 | 6 | 0.190 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 8 | 0.190 |
Why?
|
| Health Care Costs | 2 | 2021 | 229 | 0.190 |
Why?
|
| Troponin I | 1 | 2021 | 8 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 10 | 0.190 |
Why?
|
| Societies, Medical | 1 | 2021 | 75 | 0.190 |
Why?
|
| Information Dissemination | 1 | 2021 | 51 | 0.180 |
Why?
|
| Patients | 1 | 2021 | 34 | 0.180 |
Why?
|
| Sympathetic Nervous System | 1 | 2020 | 3 | 0.180 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 1 | 0.180 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 11 | 0.180 |
Why?
|
| Guideline Adherence | 2 | 2021 | 157 | 0.180 |
Why?
|
| Triage | 1 | 2020 | 16 | 0.180 |
Why?
|
| Heart Murmurs | 1 | 2020 | 1 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 3 | 0.180 |
Why?
|
| Pneumonia | 1 | 2021 | 51 | 0.180 |
Why?
|
| Research Design | 1 | 2023 | 376 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 4 | 0.180 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 304 | 0.180 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 271 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2021 | 218 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 129 | 0.170 |
Why?
|
| Hospitals | 1 | 2020 | 80 | 0.170 |
Why?
|
| Disease Progression | 2 | 2021 | 264 | 0.170 |
Why?
|
| Fever | 1 | 2020 | 55 | 0.170 |
Why?
|
| Hemodilution | 1 | 2019 | 1 | 0.170 |
Why?
|
| Benzazepines | 1 | 2019 | 24 | 0.170 |
Why?
|
| Sitagliptin Phosphate | 1 | 2019 | 3 | 0.170 |
Why?
|
| Asia | 1 | 2019 | 15 | 0.170 |
Why?
|
| Diuretics | 1 | 2019 | 17 | 0.170 |
Why?
|
| North America | 1 | 2019 | 42 | 0.170 |
Why?
|
| Europe | 1 | 2019 | 42 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2020 | 92 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 129 | 0.160 |
Why?
|
| Length of Stay | 1 | 2020 | 181 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2020 | 247 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2021 | 245 | 0.150 |
Why?
|
| Digoxin | 1 | 2018 | 12 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 455 | 0.150 |
Why?
|
| Quality of Life | 2 | 2022 | 510 | 0.150 |
Why?
|
| Heart Ventricles | 1 | 2017 | 17 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 3 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 710 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 368 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2018 | 71 | 0.140 |
Why?
|
| Administration, Sublingual | 1 | 2016 | 1 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 13 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2021 | 1101 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 44 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 26 | 0.130 |
Why?
|
| Biomarkers | 3 | 2022 | 303 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 250 | 0.130 |
Why?
|
| Time and Motion Studies | 1 | 2014 | 3 | 0.120 |
Why?
|
| Systems Analysis | 1 | 2014 | 5 | 0.120 |
Why?
|
| Efficiency, Organizational | 1 | 2014 | 32 | 0.120 |
Why?
|
| Exercise | 1 | 2018 | 492 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2014 | 194 | 0.100 |
Why?
|
| Adult | 3 | 2021 | 7678 | 0.100 |
Why?
|
| Survival Rate | 2 | 2021 | 260 | 0.080 |
Why?
|
| Health Status | 2 | 2022 | 298 | 0.080 |
Why?
|
| Incidence | 2 | 2021 | 1266 | 0.070 |
Why?
|
| Prognosis | 2 | 2021 | 609 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2023 | 8 | 0.050 |
Why?
|
| Denmark | 1 | 2023 | 18 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2021 | 7 | 0.050 |
Why?
|
| Critical Illness | 1 | 2022 | 50 | 0.050 |
Why?
|
| Natriuretic Peptides | 1 | 2021 | 5 | 0.050 |
Why?
|
| Colchicine | 1 | 2020 | 1 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2020 | 10 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 9 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2022 | 105 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 14 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 3 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 24 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2020 | 64 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 44 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 60 | 0.040 |
Why?
|
| Decision Making | 1 | 2022 | 183 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 145 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 354 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 381 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 134 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 315 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 172 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 630 | 0.040 |
Why?
|
| France | 1 | 2018 | 12 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 66 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 22 | 0.040 |
Why?
|
| Young Adult | 1 | 2021 | 2461 | 0.030 |
Why?
|
Concepts
(184)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->